Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study
The aim of this study was to evaluate the value of scheduled imaging for patients who achieved first complete remission after CHOP-like chemotherapy plus rituximab. In this retrospective cohort study, we included 759 patients newly diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) at the Cancer Institute, Japanese Foundation for Cancer Research. Relapsed patients were divided into two groups based on method of diagnosis: clinical symptoms (symptom group, n = 57) or scheduled imaging (imaging group, n = 27). Our primary goal was to compare overall survival and relapse-free survival between the two groups. No significant difference in outcomes was found between the symptom and imaging groups. Median overall survival [7.5 years; 95% confidence interval (CI) 4.0–9.7 vs. 9.1 years; 95% CI 2.7 to not reached; P = 0.747), and median relapse-free survival (1.8 years; 95% CI 1.4–2.5 vs. 2.4 years; 95% CI 1.2–4.4; P = 0.108). Surveillance imaging in patients with DLBCL who achieved first complete remission did not demonstrate an advantage in terms of overall survival or relapse-free survival.
KeywordsDiffuse large B-cell lymphoma Surveillance imaging
TF designed the study, reviewed the literature, wrote the initial draft of the manuscript, and chaired the writing group. NN, YS, and MY revised the manuscript, provided study materials, and approved the final draft of the manuscript. NT and KT diagnosed lymphoma. NI, HU, YK, YM, and YT provided study materials and approved the final draft of the manuscript.
Compliance with ethical standards
Conflict of interest
NN, YM, and MY are supported by Chugai-Roche Pharmaceuticals Co., Ltd. YT is supported by Bristol-Myers Squibb, Celgene, Janssen, Novartis Pharma, and Takeda Pharmaceutical Co., Ltd. The remaining authors declare no competing financial interests regarding this study.
- 4.Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure—what to do? ASH Educ Progr Book. 2016;2016:366–78.Google Scholar